Last reviewed · How we verify

CG100649 — Competitive Intelligence Brief

CG100649 (CG100649) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cathepsin S inhibitor. Area: Immunology.

phase 3 Cathepsin S inhibitor Cathepsin S Immunology Small molecule Live · refreshed every 30 min

Target snapshot

CG100649 (CG100649) — CrystalGenomics, Inc.. CG100649 is a selective inhibitor of cathepsin S that reduces inflammatory responses by modulating immune cell activation and antigen presentation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CG100649 TARGET CG100649 CrystalGenomics, Inc. phase 3 Cathepsin S inhibitor Cathepsin S

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cathepsin S inhibitor class)

  1. CrystalGenomics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CG100649 — Competitive Intelligence Brief. https://druglandscape.com/ci/cg100649. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: